Leveraged Finance Fights Melanoma

June 16, 2022 | 7:00 pm ET.

Join us for cocktails & hors d’oeuvres at the MoMA Sculpture Garden!

Museum of Modern Art
Lobby & Sculpture Garden
18 West 54th Street
New York, NY

Add to Calendar

Purchase Individual Tickets

Sponsorship Opportunities

Sponsor Registration

Over ten years, LFFM has raised more than $16 million to advance 21 grants for cutting-edge melanoma research. LFFM’s support of MRA has not only helped improve survivorship for melanoma patients, but has allowed MRA to champion revolutions in immunotherapies, targeted therapies, and novel combinations that are now being used in many other cancer types

Please email Janine Rauscher with any questions or to sponsor.


Event Chairs: Clare Bailhé (MidCap Financial), Brendan Dillon (Veritas Capital), Kerry Dolan (Brinley Partners), Lee Grinberg (Elliott Management), Matt Manin (Apollo), George Mueller (KKR), Geoff Oltmans (Silver Lake), Kevin Pluff (UBS Financial), Jeff Rowbottom (Iron Park Capital), Ian Schuman (Latham & Watkins), Cade Thompson (KKR), Trevor Watt (Hellman & Friedman), & Eric Wedel (Kirkland & Ellis)


About LFFM: Spotlighted in publications like Forbes, Bloomberg and The New York Times, the Leveraged Finance Fights Melanoma (LFFM) event has become the premier gathering of professionals from the leveraged finance, private equity, and investment communities who come together to fight melanoma, the deadliest form of skin cancer. Some of the most prominent names in the industry —Carl Icahn, Mike Milken, Leon Black, Henry Kravis and Howard Marks—have been featured.

The annual event raises critical funds for melanoma research and awareness on skin cancer prevention. Founded in 2011 by Jeffrey Rowbottom and Brendan Dillon—both of whom combatted melanoma— the LFFM event has raised more than $16 million that goes directly to research.

Advances in melanoma research supported by MRA have changed the landscape dramatically for patients, with 13 of the 15 treatment options coming to market since the event’s kick-off. These advances have created a ripple effect across the field of oncology. Drugs first approved in melanoma are now being tested in more than 30 cancers. 


LFFM1

 LFFM Sponsors:

 LFFM2022 Sponsors 5.16.22

MRA web ad 1000x100

Login

×